治疗性进步在埃索诺菲尔颗粒瘤与多炎的治疗
Jessica L Bloom1, Carol A Langford2, Michael E Wechsler3
1Section of Rheumatology, Department of Pediatrics, University of Colorado School of Medicine, 13123 East 16th Avenue B-311, Aurora, CO 80045, USA.
Rheumatic diseases clinics of North America
|June 18, 2023
概括
带有多炎的埃索诺菲尔颗粒炎 (EGPA) 是一种影响多个器官的埃索诺菲尔血管炎. 针对性治疗的最新进展显著改善了患者的治疗结果,更多的治疗方法在地平线上.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 血管医学 血管医学
背景情况:
- 带有多炎的异性粒状炎 (EGPA) 是一种罕见的全身性血管炎,其特征是异性透和炎症.
- 从历史上看,管理依赖于广泛的免疫抑制剂,如葡萄糖皮质类药物,往往导致显著的副作用.
- 这种疾病会影响各种器官系统,包括呼吸道,皮肤和神经.
研究的目的:
- 审查EGPA管理的不断变化的格局.
- 突出新型向治疗对患者结果的影响.
- 讨论EGPA新出现的治疗策略.
主要方法:
- 临床试验和观察性研究的文献综述.
- 对传统和向疗法的治疗反应的分析.
- 综合目前对EGPA病理生理学和治疗的理解.
主要成果:
- 与历史治疗相比,向疗法已经证明了优越的疗效和安全性.
- 疾病控制和减少器官损伤的显著改善已经被观察到.
- 越来越多的目标特工正在接受调查,有望取得进一步进展.
结论:
- 针对性疗法已经彻底改变了EGPA的管理.
- 这些新的治疗方法为EGPA患者提供了改善的结果和生活质量.
- 对新型治疗点的持续研究对于优化EGPA护理至关重要.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
204
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
204
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
357
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
357
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
221
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
221
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212
Nephrotic Syndrome II : Assessment and Medical Management
10
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
10
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


